Dermata Therapeutics (DRMA) Projected to Release Earnings on Wednesday

Dermata Therapeutics (NASDAQ:DRMA) will likely be announcing its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to announce earnings of ($0.55) per share and revenue of $0.03 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 7:00 AM ET.

Dermata Therapeutics (NASDAQ:DRMA) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.55) EPS for the quarter, meeting analysts’ consensus estimates of ($0.55). The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.03 million.

Dermata Therapeutics Stock Performance

Shares of NASDAQ DRMA opened at $0.71 on Wednesday. Dermata Therapeutics has a twelve month low of $0.60 and a twelve month high of $4.66. The company has a 50 day moving average of $1.00 and a 200 day moving average of $1.27.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dermata Therapeutics in a research note on Monday, October 26th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Dermata Therapeutics

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases. The company’s research is centered on topical therapies intended to address common inflammatory and dermatologic conditions. Its lead product candidate, DMT310, is a once-weekly topical treatment being evaluated for conditions including psoriasis and acne vulgaris. The therapy is based on a proprietary platform derived from a naturally occurring freshwater sponge and is designed to deliver localized treatment to the skin.